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ABSTRACT 
Miller, Elizabeth F., The effect of CLA supplementation on fat deposition and lean muscle 
mass in horses. Master of Science (Agriculture), May, 2017, Sam Houston State 
University, Huntsville, Texas. 
 
Fatty acids are utilized within the equine industry to increase the caloric density 
of a diet as well as replace soluble carbohydrates. Omega-3 fatty acids are the most 
commonly supplemented fatty acids due to their potential health benefits; however, 
palatability limitations have spurred an investigation into alternative fatty acids like 
conjugated linoleic acid (CLA). CLA has shown health benefits similar to that of omega-
3s, but the effect of CLA on equine fat deposition and lean muscle mass has yet to be 
established. The purpose of this investigation was to evaluate the effects of 
supplementing elevated levels of CLA on both lean muscle mass and fat deposition in 
young growing horses. In phase I of this study, 10 Quarter horses were fed between 5.0% 
and 10.0% of the concentrate diet, increasing the supplementation level every 3 d to 
determine the maximum inclusion rate of CLA in horses. In phase II, 9 Quarter horses 
were separated into 2 treatment groups fed either a control diet of soybean oil or CLA (n 
= 4 and 5/group, respectively) for 12-wks with BW and sex evenly distributed across 
treatments. Diets were formulated to be isocaloric and isonitrogenous and each treatment 
was offered at 0.015% BW/d. Growth measurements were collected weekly; rump fat 
thickness (RFT), ribeye area (REA), back fat (BF) and intramuscular fat (IMF) were 
measured on d 7, d 42, and d 84 of the feeding period. The MIXED procedure in SAS 
was used with repeated measures to detect differences in growth performance and 
ultrasound measurements. There were no differences in performance characteristics or fat 
content between treatment groups (P > 0.05). In order to account for initial differences 
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between treatments (P < 0.05); REA between the 17th and 18th ribs (REA17) was run 
with d 7 as a covariate. Mean REA17 tended to be higher in CLA supplemented horses (P 
< 0.07) when compared to controls. These results suggest that in an equine model, CLA 
does not affect growth performance or fat deposition, but may increase lean muscle mass 
in young growing horses. Further studies examining these effects over longer 
supplementation periods or in obese or insulin-resistant horses may offer insight to 
potential benefits of CLA in the horse. 
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Horses are considered hindgut fermenters and have the ability to digest cellulose 
and hemicellulose that other classic monogastrics, like humans and swine, cannot due to 
specific microbes acting within a well-developed cecum. It is common practice within the 
performance horse industry to feed soluble carbohydrates in the form of concentrates to 
meet digestible energy requirements. However, even with adequate access to forages, 
these high starch diets can cause starch overload, a condition that occurs when soluble 
carbohydrates are not digested in the small intestine and as a result travel undigested 
through the small intestine before moving into the cecum, where it undergoes 
fermentation. The fermentation of starch causes a sharp drop in cecal pH, which can kill 
the microbes responsible for fiber digestion and may result in colic, laminitis, or founder. 
Lipid supplementation is a safer alternative to high starch diets due to its high energy 
density, allowing for increased caloric intake while preventing the starch overload that 
could result from feeding a high concentrate diet alone. The equine industry utilizes high-
fat diets in several ways, such as in pregnant or lactating mares, performance horses, and 
horses with a high sensitivity to starch or glucose.  
Similar to what is seen with human nutrition, some fats are healthier to 
supplement in horses than others. For instance, omega-3 fatty acids are known to elicit a 
number of health benefits and as such are the preferred ingredients of commercial fat 
supplements over their omega-6 counterparts, even though both are essential nutrients 
and must be included in the diet daily. There are a number of different fat supplement 
products on the market that are derived from a variety of sources with varying fatty acid 
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composition. Omega-3 fatty acids are typically supplied in the diet from marine-based 
sources such as menhaden fish oil or vegetable derived flaxseed oils. However, these 
common sources of omega-3s have poor conversion efficiency into active ingredients as 
well as palatability limitations. One fatty acid that has garnered significant scientific 
attention in the past few decades for its potential health benefits and improved 
palatability is conjugated linoleic acid (CLA). It is found naturally in meat and dairy 
products and is marketed as a health supplement in both humans and livestock.  
Previous study regarding CLA supplementation in other species, like swine and 
rats, has shown a number of health benefits, such as the reduction body fat accumulation. 
However, its use in horses has been minimal to this point and as such; its effects in an 
equine model are not fully known. The objective of the current study is to determine the 
maximum inclusion rate of supplemental CLA to young developing horses and to 
evaluate the effects of supplementing elevated levels of CLA on body composition. 
Demonstrating the positive physiological benefits of a CLA-supplemented diet will have 
significance to the health and well-being of all horses, regardless of breed or discipline. 
In particular, the ability of CLA to reduce the accumulation of adipose tissue could have 
a significant impact on horses with equine metabolic syndrome (EMS), a disease 
associated with insulin resistance, obesity, and subsequent laminitis. Additionally, CLA 
could have applications within various equine disciplines, increasing lean muscle mass 
and modulating the fat accumulation in young growing horses, competitive performance 






Conjugated linoleic acid (CLA) refers to a group of positional and stereoisomers 
of conjugated octadecadienoic acid (18:2), or linoleic acid (Headley et al., 2012; Lehnen 
et al., 2015; Ostrowska 1999; Wang and Lee, 2013). It is naturally found in beef, lamb, 
and dairy products, predominantly as the c9,t11-CLA isomer, also known as rumenic 
acid, which is formed as an intermediate in the biohydrogenation of polyunsaturated 
linoleic acid to saturated stearic acid by the rumen bacteria Butyrinvibrio fibrisolvens, 
Lactobacillus acidophilus, Propionibacterium freudenreichi, and others (Belury, 2002; 
Derakhshande-Rishehri et al., 2014; Eftekhari et al., 2013; Kim et al., 2016; Koba and 
Yanagita, 2014; Lehnen et al., 2015; Thiel-Cooper et al., 2001; Wang and Lee, 2013). 
While CLA is made up of several isomers of linoleic acid, previous studies have shown 
that specific isomers are responsible for the different physiological effects attributed to 
CLA supplementation. Along with the c9, t11-CLA isomer, the t10, c12-CLA is the other 
important isomer exhibiting positive health effects. For instance, it has been shown that 
the t10,c12-CLA isomer is primarily responsible for the reduction of body fat gain, 
whereas both the c9,t11- and t10,c12-CLA isomers appear to be effective in inhibiting 
carcinogenesis (Belury, 2002; Kim et al., 2016; Koba and Yanagita, 2014; Pariza, 2004; 
Wang and Lee, 2013). Synthetic preparation of CLA will produce roughly equal amounts 
of both predominant forms of CLA as well as a small amount of other minor isomers, 
such as t9,t11-CLA. While these other isomers may also exhibit additional health 
benefits, c9, t11 and t10, c12-CLA are the main isomers in question. The method of 
action is dependent on both the specific isomer and what physiological process it affects, 
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and in some cases, is still unclear (Kim et al., 2016; Lehnen et al., 2015; Wang and Lee, 
2013).  
Like any other supplemental oil, CLA isomers will accumulate in tissues when 
fed and are readily metabolized by several pathways. CLA metabolites have been 
identified in the liver, and mammary tissue of rats and the adipose tissue of humans 
(Belury, 2002). CLA isomers are metabolized similarly to linoleic acid – producing 
conjugated arachidonic acid (20:4) through a series of desaturase and elongase reactions. 
Additionally, CLA can be oxidized to β-oxidation products (16:1 and 16:2), although the 
role these metabolites play in the modulation of adipose tissue mass, glucose sensitivity, 
and carcinogenesis has yet to be elucidated (Belury, 2002). Pariza (2004) reviewed 
previous literature examining the effects of CLA supplementation in various species, with 
some researchers concerned that CLA could potentially induce insulin resistance, fatty 
liver, or lipid peroxidation. Despite these concerns, no conclusive adverse effects have 
been observed as a result of CLA inclusion in the diet. For instance, it has been suggested 
that the effect of CLA on glucose homeostasis and insulin resistance may be temporary 
due to changes in lipid metabolism. Additionally, while some reports show that CLA may 
increase oxidative stress markers, the mechanism of action is not well understood, 
whereas many other studies have shown a decrease in not only oxidative stress markers 
but anti-inflammatories as well (Kim et al, 2016; Viladomiu et al., 2016). Basirico et al. 
(2015) showed the ability of CLA supplementation to act as an antioxidant, protecting 
against oxidative stress by increasing nicotinamide adenine dinucleotide phosphate 
(NADPH) and glutathione (GSH) availability without inducing the production of reactive 
oxygen species (ROS). CLA has the potential to act much like dietary omega-3 fatty 
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acids when supplemented, which have been shown to benefit the health of many species 
(Hall et al., 2004; King et al., 2008). 
Previous investigation on CLA supplementation has shown that it elicits many 
beneficial physiological properties, including acting as an anticarcinogenic and 
antiadipogenic agent as well as affecting bone formation and lipid metabolism (Belury, 
2002; Derakhshande-Rishehri et al., 2014; Eftekhari et al., 2013; Kim et al., 2016; Koba 
and Yanagita, 2014; O’Quinn et al., 2000; Ostrowska et al., 1999; Pariza, 2004). The 
anticarcinogenic effect of CLA has been evaluated in many experimental animals, 
particularly in rats and mice. Several studies reviewed by Belury (2002) have shown 
significant reduction in the development of mammary, prostate, and skin carcinogenesis 
when animals were fed a diet supplemented with CLA, though some studies show 
inconsistent results. CLA is believed to inhibit both the initiation stage of carcinogenesis 
as well as tumor promotion, although its role has not yet been fully elucidated. Potential 
mechanisms include modulating free radical oxidation of cells, carcinogen metabolism, 
carcinogen-DNA adduct formation, and the induction of apoptosis (Belury, 2002). In 
postmenopausal women, there is evidence of CLA exhibiting protective effects against 
estrogen-dependent types of breast cancer by regulating estrogen receptor (ER) signaling 
pathways, inhibiting cancer cell growth, and increasing apoptosis in ER-positive breast 
cancer cells (Kim et al., 2016). CLA may also exert an anticarcinogenic effect is through 
the activation of peroxisome proliferator-activated receptors (PPARs). PPARs are 
transcription factors that regulate the expression of genes involved in energy regulation, 
glucose homeostasis, and immune function (Viladomiu et al., 2016). PPAR, for instance, 
has been shown to induce apoptosis, while both PPAR and PPAR inhibit the 
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proliferation of several types of cancer by inhibiting nuclear factor (NF)-B and activator 
protein 1 (AP1) activation in cancerous cells (Koba and Yanagita, 2014). CLA may be 
incredibly beneficial for cancer patients when used in conjunction with other current 
treatments, especially since the anti-inflammatory properties of CLA may also serve to 
prevent the increased inflammatory responses associated with radiotherapy.  
 While not much CLA research has been directed towards horses, there is much 
potential within the equine industry for CLA use that warrants further exploration. One of 
the benefits that would be immensely useful in the equine industry is the ability of CLA 
to reduce the accumulation of adipose tissue. This has already been demonstrated in 
several species, such as pigs, rats, mice, and humans. Several studies have shown that 
supplementing CLA to the diet improves carcass quality by increasing the rate and 
efficiency of gain, reducing fat deposition, and increasing lean tissue in swine. These 
changes not only improve the quality of meat produced but also help produce less waste 
by increasing yield and decreasing the cost of production due to increased average daily 
gain (O’Quinn et al., 2000; Ostrowska et al., 1999; Thiel-Cooper et al., 2001; Zhang et 
al., 2016). A similar effect has been reported in rats, where the improvement of liver 
function and modification of lipid metabolism in insulin-resistant rats was seen when 
CLA was supplemented at 1.5% (Chin et al., 1994; Noto et al., 2006). CLA 
supplementation, particularly the t10, c12-CLA isomer, also inhibits milk fat synthesis in 
dairy cows, which may cause a shift in energy partitioning towards other milk 
constituents, like protein and lactose, while preventing the excessive mobilization of 
lipids. This not only improves the protein yield in the milk but also stabilizes the health 
of the cow at the onset of lactation (Ghazal et al., 2014; Masur et al., 2016). The effect of 
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CLA supplementation in humans has been variable, for instance, Madry et al. (2016) 
reported that CLA did not affect body weight reduction or BMI but did decrease hip 
circumference. However, it is likely that these effects on adiposity are species dependent 
or dependent on preexisting adiposity, making the exploration of CLA’s effects on 
different species essential to understanding its potential benefits. 
The mechanisms by which CLA reduces adiposity may involve pathways that 
regulate energy expenditure, energy intake, and gene expression of lipid and muscle 
metabolism. The body composition changes that occur with CLA supplementation are a 
result of CLA’s effects on adipocyte and muscle metabolism, including enhanced fat 
utilization in the muscle through -oxidation and the reduction of lipid storage, synthesis, 
and adipogenesis in adipocytes (Kim et al., 2016; Lehnen et al., 2015). CLA may also 
target skeletal muscle metabolism; it has been shown that CLA supplementation 
increases lean body mass, energy expenditure, and mitochondrial biogenesis through the 
regulation of AMP-activated protein kinase (AMPK), which subsequently activates 
PPAR coactivator-1 (PGC-1) and PPAR-. Increased mitochondrial biogenesis 
causes a transformation of muscle fibers from glycolytic fast-twitch type IIB to oxidative 
slow-twitch type I (Kim et al., 2016). Since type I muscle fibers utilize lipids for energy 
more than type IIB fibers, this shift in muscle fiber type also increases lipolysis in 
adipocytes to provide an energy source for muscle fibers. CLA is a potent ligand and 
activator of PPARs, and as such can activate PPAR-regulated lypolytic genes, including 
carnitine-palmitoyl transferase (CPT), acyl CoA odixase, and uncoupling protein (UCP) 
(Koba and Yanagita, 2014; Lehnen et al., 2016). An increase in CPT and UCP 
concentration and activity increases mitochondrial lipolysis in muscle fibers while 
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simultaneously reducing the fatty acids and triglycerides available for accumulation in 
adipose and muscle tissue (Kim et al., 2016; Lehnen et al., 2016). The reduction of body 
fat may also be a result of CLA’s regulation of genes through PPAR inhibition, 
particularly the genes that control the differentiation of pre-adipocytes to mature 
adipocytes, which reduces lipogenesis (Lehnen et al., 2016; Masur et al., 2016).  
If CLA can be shown to increase lean muscle mass while decreasing fat 
deposition in horses, it could be of great use within the equine industry, with the potential 
to increase lean muscle mass in working and performance horses and to help manage 
horses with equine metabolic syndrome (EMS). Frank et al. (2010) reviewed this disease 
that links the presence of obesity, insulin resistance, and laminitis to one clinical 
syndrome affecting both horses and ponies. Additional symptoms include bilateral 
lameness and cresty neck scores at or above three using the scale detailed in Carter et al. 
(2009). Because there is no cure for this syndrome, horses with EMS must be strictly 
managed, lowering the level of non-structural carbohydrates (NSC), digestible energy 
(DE), and pasture grass accessible to the horse while also increasing their exercise 
regimen. These dietary restrictions make a high fiber, fat supplemented diet an attractive 
option for horses with EMS, specifically utilizing CLA for its antiadipogenic capabilities. 
CLA enhances insulin sensitivity by activating PPAR, which is widely used as treatment 
for type 2 diabetes in humans. PPAR activation increases plasma adiponectin 
concentrations and causes the translocation of glucose transporter-4 (GLUT4) to the 
plasma membrane via the activation of 5’-AMP-activated protein kinase (AMPK). This 
not only helps improve hyperinsulinemia but also increases glucose uptake in skeletal 
muscle, which may help normalize glucose metabolism in insulin resistant individuals 
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(Cho et al., 2016; Koba and Yanagita, 2014). CLA has also been shown to significantly 
decrease LDL levels and may also lower total cholesterol and triacylglycerol (TAG) 
levels while increasing HDL concentrations. It has been suggested that CLA decreases 
LDL levels by inhibiting the secretion of apolipoprotein B (apo B) or by increasing the 
clearance rate of circulating LDLs through increased LDL receptor activity. CLA may 
also decrease TAG levels by inhibiting the expression of hepatic stearoyl-CoA 
desaturase, which is an enzyme involved in TAG synthesis (Derakhshande-Rishehri et 
al., 2014).  
The anti-inflammatory effect of CLA has been reported in several animal models 
and would also be immensely beneficial to the equine industry if it is shown to be 
effective in horses. It is believed that CLA can modify the immune response by 
regulating the production of soluble factors and inflammatory molecules. Both major 
isomers of CLA have been shown to decrease immune responses by lowering the activity 
of monocytes, macrophages, dendritic cells and natural killer cells while also decreasing 
the production of prostaglandins and leukotrienes (Viladomiu et al., 2016). CLA also 
increases the production of IgG, IgM, and IgA while suppressing IgE, IL-12, and PGE2 
expression, all of which contribute to airway inflammation during an allergic reaction 
(Jaudszus et al., 2016; Kim et al., 2016; Viladomiu et al., 2016). CLA can act as a 
modulator of T-cell responses by enhancing the cytotoxic potential of blood lymphocytes 
and proliferation of TCRCD8 cells, both of which help modulate the phenotype and 
functions of CD8+ cells that are involved with both adaptive and innate immunity. 
Furthermore, CLA is able to alter the differentiation of monocytes to macrophages, which 
controls the subsequent activation and differentiation of T- and B-cells (Viladomiu et al., 
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2016). Another way in which CLA effects the immune response is through modulating 
cytokine expression. CLA can diminish the production or activation of pro-inflammatory 
cytokines, such as IL-6, TNF, IFN, IL-1, and nuclear factor kappa B (NF-B). One 
way that CLA is able to regulate cytokine production is through PPARs. When activated 
by CLA, PPARs like PPAR inhibit the transcription of these pro-inflammatory 
cytokines (Eftekhari et al., 2013; Kim et al., 2016; Viladomiu et al., 2016). Through 
PPAR and retinoic acid X receptor (RXR), CLA may also combat oxidative stress caused 
by ROS formation when supplemented at a rate of 1-2% of the diet (Moraes et al., 2016). 
CLA may be able to prevent an inflammatory response by inhibiting inflammatory 
prostaglandin (PG) production, and subsequent PGE2 and PGF2α production, through a 
NF-B dependent signaling mechanism. For instance, Badinga et al. (2016) reported that 
CLA was able to decrease lipopolysaccharide (LPS)-induced release of PG and 
hypothesized that CLA may act by preventing nuclear translocation of NF-B.  
Because there are considerable differences in the effect of CLA on different 
species, there is still much about the effects of CLA that is unknown, especially in the 
horse. Previous work with horses has reported lower concentrations of inflammatory 
agent collagenase cleavage neopeptide (C2C) and higher concentrations of 
carboxypeptide of type II collagen (CPII), an anti-inflammatory agent. This suggests that 
supplementing CLA can help stimulate cartilage synthesis and mitigate degradation of 
the joints after an inflammation challenge (Bradbery et al., 2014). This work is consistent 
with literature reviewed by Viladomiu et al. (2016), showing the ability of CLA to 
moderate inflammation responses. Headley et al. (2012) showed that supplementing CLA 
to horse diets can alter circulating fatty acid levels, decreasing plasma arachidonic acid 
11 
 
concentrations as well as serum triglycerides and total cholesterol. However, they did not 
observe any changes in body condition or body weight as a result of supplementation at a 
rate of 0.30% of daily diet. Because they relied on a crossover design, Headley et al. 
(2012) recommended that further research involving longer supplementation and 
withdrawal periods may help clarify some of their results and eliminate the treatment x 
day interaction they experienced during their crossover experiment. Elevating the level of 
CLA supplementation could also further clarify any effect CLA may have on body fat 
deposition and anti-inflammatory properties in horses. If CLA can be shown to elicit 
positive anti-inflammatory effects in horses, it would be immensely beneficial within the 
equine industry, particularly regarding competition or performance horses that undergo 
elevated levels of stress.  
Several different methods have been developed to determine fat accumulation and 
muscle mass or thickness in horses. The most widely accepted and utilized method for 
determining body fat and overall condition in horses is the Henneke (1983) body 
condition scoring system. This subjective method utilizes a scale from one to nine – one 
being extremely thin and nine being extremely obese – assessed both visually and by 
palpation over six major points of fat accumulation on the body. Similarly, the crest 
scoring system is another subjective method of measuring body fat using a scale from 
zero to five – zero being no neck crest visible or palpable and five being a neck crest so 
large it droops permanently to one side (Carter et al., 2009). While these methods are 
more commonly used by the equine industry, they do not provide an objective means of 
evaluating body fat and overall condition. One noninvasive way of quantifying body 
condition involves taking transdermal ultrasound imaging of different muscle groups to 
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measure both muscle thickness, cross-sectional area, and rump fat thickness (Linder et 
al., 2010). While ultrasounds do provide a means of objectively quantifying muscle and 
fat composition, they are not necessarily a practical or readily available means of 






The purpose of this investigation was divided into multiple phases: 
Phase I: Determine the maximum inclusion rate of supplemental CLA to young 
developing horses.  
Phase II: Evaluate the effects of supplementing elevated levels of CLA on growth 





Materials and Methods 
All experimental procedures were approved by the Sam Houston State University 
(SHSU) Institutional Animal Care and Use Committee prior to the start of the experiment 
(16-09-08-1008-3-01). Horses were housed at the SHSU Agricultural Center in 3 x 3 m 
individual stalls for the duration of this study and were used in conjunction with the 
Equine Behavior and Training courses (EQSC 3340 Equine Behavior and Training I; 
EQSC 4391 Equine Behavior and Training II). 
Phase I: Determining Palatability 
Ten Quarter horses (2-6 yrs, 435.53 kg) from private owners were utilized to 
determine the highest level of CLA supplementation that is palatable to horses. Horses 
were fed at 1% of body weight (BW) daily of a commercially available pelleted 
concentrate (SafeChoice, Cargill Animal Nutrition, Elk River, MN) and approximately 
1% BW of coastal bermudagrass hay divided equally between two meals. Diets were 
formulated to meet or exceed all NRC (2007) nutritional requirements for mature horses 
performing light exercise. Soybean oil is the most readily available and widely utilized by 
the equine industry as a fat supplement, and as such was utilized to provide a baseline 
level of fatty acid palatability in an equine model. Soybean oil was topdressed onto feed 
and mixed immediately prior to each meal beginning at 5.0% per day of the total 
concentrate diet. Every three days, horses were weighed before their morning feeding, 
and the level of oil supplementation was increased if no significant refusals were 
observed during the previous feeding period. Once significant refusals were discerned, 
the level of supplementation was decreased until palatability returned. For each meal, 
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horses were given one hour to eat before refusals were collected and weighed. Once a 
supplementation level was discerned with the soybean oil, CLA (BASF Corp., Florham 
Park, NJ) was substituted for soybean oil to ensure palatability was the same across 
treatments. The same protocol for supplementation rate and feeding were applied for both 
soybean oil and CLA supplementation. Changes in intake levels across the different oils 
and levels of supplementation were analyzed using the PROC GLM procedure in SAS v. 
9.4 (SAS Inst. Inc., Cary, NC). Effects were considered significant when P ≤ 0.05. 
Phase II: CLA Supplementation 
Nine stock-type horses (1-3 yrs, 384.45 kg) from private owners were utilized in a 
12-week completely randomized design where horses were randomly assigned to 
treatment groups of either CLA (BASF Corp., Florham Park, NJ) or soybean oil control 
(n = 5 and 4/group, respectively) with age, BW, and sex evenly distributed across 
treatments. Horses were fed at 1% BW daily of a commercially available pelleted 
concentrate (SafeChoice, Cargill Animal Nutrition, Elk River, MN) and approximately 
1% BW of coastal bermudagrass hay divided equally between two meals. Diets met or 
exceeded all NRC (2007) nutritional requirements for mature horses performing light 
exercise. Both control and treatment groups were supplemented at 1.5% of the total 
concentrate diet (0.015% BW) and were topdressed onto feed and mixed immediately 
prior to each meal. Diet adaptation took place over a 12 d period prior to the start of the 
trial, with the first 6 d being adaptation to the concentrate feed and to ensure all horses 
begin the trial on a consistent plane of nutrition. Oil supplementation began 6 d prior to 
the beginning of the study in order to acclimate horses to the treatment. They received 
25% of total treatment dose on the first day of oil supplementation and was increased 
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every 2 d by 25% so that they received their full ration on d 0.  
Starting on d 0, data collection entailed weekly body weights (BW) on fasted 
horses as well as body condition score (BCS), heart girth, crest circumference, and crest 
score to assess body composition and to reformulate diets while blood was collected 
biweekly. Heart girth and crest circumference were measured with a soft tape measure 
placed around the heart girth and at the approximate center of the neck where a horse 
would have the greatest crest circumference. A single, trained individual determined BCS 
and crest score each week utilizing the scales outlined in Henneke (1983) and Carter et al. 
(2009), respectively. Rump fat thickness (RFT), ribeye area (REA), back fat thickness 
(BF), and intramuscular fat (IMF) measurements were conducted via transdermal 
ultrasonography by the same centralized ultrasound processing (CUP) certified technician 
using an ultrasound system (Aloka SSD-500V, Aloka Inc., Tokyo, Japan) in conjunction 
with a 3.5 MHz 172 mm linear transducer. Measurements were taken on d 0, midway 
through the trial period (d 42), and at the completion of the trial (d 84). Images were 
analyzed by Designer Genes Technologies (Harrison, AR). REA and BF were obtained 
via a cross-sectional image between the 13th and 14th ribs (REA13 and BF13, 
respectively) and between the 17th and 18th ribs (REA17 and BF17, respectively). RFT 
was measured at 5 cm lateral from the midline halfway between the first coccygeal 
vertebrae and the ischium (Westervelt et al., 1976). IMF measurements within the 
longissimus dorsi were obtained by imaging parallel to the backbone between the 17th 
and 18th ribs. To ensure proper contact between transducer and horse, the transducer was 
fitted with a PIA contour pad (Animal Ultrasound Services, Ithaca, NY) designed to 
conform to the curvature of a horse’s back. In addition, corn oil was applied to promote 
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acoustical contact between animal and transducer (Perkins et al., 1992). Changes in 
growth performance, subjective body composition, and ultrasound measurements were 
analyzed using PROC MIXED with repeated measures in SAS with the main effects of 
treatment and time included in the model. Additionally, PROC GLM was used to 







 From phase I of this study, horses were observed to consume no more than 5.0% 
CLA of the concentrate diet daily without significant refusal (Figure 1) with the range of 
fatty acid supplementation ranging from 5.0% to 10.0% of the total daily concentrate diet. 
Soybean oil supplementation exhibited a difference between the 5.0% and 10.0% 
supplementation levels (P < 0.05) but not between the 5.0% and 7.5% supplementation 
levels (P = 0.13). Higher refusals were observed when CLA was supplemented at 7.5% 
compared to when it was supplemented at 5.0% (P < 0.01). At the 5.0% supplementation 
level, there was no difference between soybean oil and CLA (P = 0.48); however, above 
a 5.0% supplementation level, CLA exhibited higher refusals than soybean oil (P < 0.01). 
For phase II, the inclusion rate was determined at 2.5% of the concentrate diet. However, 
significant refusals of both treatment oils were observed during the adaptation period of 
phase II when treatment and control oils were supplemented at a rate above 1.5% of the 
concentrate diet. Therefore, to ensure palatability throughout the trial period, treatments 
for phase II of this study were included at 1.5% of the concentrate diet. 
Body Composition 
On occasion throughout the supplementation period, individual horses in both 
treatment groups did not consume the entirety of their meals. However, daily intake did 
not differ across treatments (P > 0.05) at any time throughout the trial (Figure 2). In 
general, body composition measurements including BW, BCS, heart girth, crest score, 
and crest circumference for horses consuming either CLA or soybean oil (CON) did not 
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differ across treatments (Table 1). BW and BCS increased over time (P < 0.01), but did 
not exhibit a difference between treatments (P = 0.17 and 0.20, respectively) or a 
treatment x day interaction (P = 1.00 and 0.65, respectively). As expected from the 
increase in BW and BCS, heart girth, crest circumference, and crest score also increased 
over time (P < 0.01). Neither crest circumference nor crest score differed across 
treatments (P = 0.55 and 0.82, respectively), nor was there a treatment x day interaction 
for either variable (P = 0.25 and 0.61, respectively). There was, however, a tendency for 
heart girth to be higher in CLA supplemented horses over time (P = 0.07).  
Ultrasound 
 Initial ultrasound measurements were recorded on d 0; however, initial data were 
lost in a computer crash and were unable to be recovered. As a result, initial 
measurements were retaken on d 7. Similar to the changes observed in growth 
performance, REA13, BF13, REA17, BF17, IFM, and RFT generally did not differ 
across treatments (Table 2). REA13 and BF13 increased over time (P < 0.01 and 0.05, 
respectively) but did not exhibit a treatment x day interaction (P = 0.69 and 0.95, 
respectively) or differ across treatments (P = 0.22 and 0.15, respectively). REA17 
exhibited a treatment x day interaction (P < 0.05). However, because REA17 in CLA 
supplemented horses (103.69 cm2 ± 2.364) was higher than control horses (91.96 cm2 ± 
2.643) on d 7 (P = 0.04), REA17 was reanalyzed with d 7 as a covariate for all 
subsequent measures to account for this initial difference (Figure 3). After accounting for 
the initial variance, REA17 tended to be higher in treatment horses (100.98 cm2 ± 2.62) 
than control horses on d 42 (91.44 cm2 ± 2.994; P < 0.07). Similarly, on d 84, REA17 
tended to be higher in treatment horses (106.91 cm2 ± 2.296) than control horses (98.389 
20 
 
cm2 ± 2.621; P < 0.07). BF17 tended to be different over time (P = 0.07) but did not 
exhibit a difference across treatments (P = 0.30) or a treatment x day interaction (P = 
0.88). IMF did not differ over time (P = 0.86), across treatments (P = 0.96) or a treatment 
x day interaction (P = 0.55). RFT increased over time (P < 0.01), but did not differ across 




Figure 1. Phase I Refusals. Mean refusals (kg) for each level of supplementation during 
the palatability phase of this study. Supplementation rate is given as a percent of total 
daily concentrate diet of either soybean oil (SBO) or conjugated linoleic acid (CLA). 
Pooled Standard error of the treatment mean was used as an indication of variation. 






























Figure 2. Phase II Intake. Mean daily intake (kg) per week for both control and treatment 
groups during phase II. Intake did not differ across treatments at any time throughout the 






























Mean BW (kg), BCS, heart girth (cm), crest score, and crest circumference (cm) for 
horses consuming either soybean oil (CON) or CLAa. 
 






SEc Trt Day Trt * Day 
BW (kg) 385.74 424.82 12.872 0.17 < 0.01 1.00 
BCS 5.50 5.88 0.151 0.20 < 0.01 0.65 
Heart Girth (cm) 169.03 173.22 2.132 0.34 < 0.01 0.07 
Crest Score 1.73 2.03 0.304 0.61 < 0.01 0.82 
Crest Circumference (cm) 87.07 90.78 1.728 0.25 < 0.01 0.55 
 
a – Conjugated linoleic acid supplement manufactured by BASF Corp. (Florham Park, 
NJ). 
b – P-values for main effects of treatment, day, and the interaction of treatment and day. 







Mean ultrasound measurements for both soybean oil (CON) and treatment (CLAc) groups on d 7, 42, and 84. 
















REA17f (cm2) 90.08a 99.94b 4.459 0.04  91.44 100.98 4.459 0.07  98.39 106.91 4.459 0.07 
BF17g (cm) 0.37 0.45 0.0308 0.30  0.29 0.34 0.0308 0.54  0.43 0.46 0.0308 0.70 
REA13h (cm2) 82.26 85.86 0.6212 0.38  77.53 83.34 0.6212 0.16  91.13 92.34 0.6212 0.77 
BF13i (cm) 0.42 0.59 0.0503 0.21 0.32 0.48 0.0503 0.23 0.47 0.67 0.0503 0.15 
IMFj (%) 3.54 3.73 0.3264 0.56  3.77 3.65 0.3264 0.72  3.72 3.69 0.3264 0.92 
RFTk (cm) 0.55 0.76 0.1148 0.50  0.81 0.94 0.1148 0.66  0.87 0.86 0.1171 0.43 
 
a-b – Within day, means with different superscripts differ at P ≤ 0.05. 
c – Conjugated linoleic acid supplement manufactured by BASF Corp. (Florham Park, NJ). 
d – The initial difference in REA17 on d 7 was accounted for by re-analyzing d 42 and 84 with d 7 as a covariate. 
e – Pooled Standard error of the treatment mean. 
f – Ribeye area between the 17th and 18th ribs in cm2. 
g – Fat content between the 17th and 18th ribs in cm. 
h – Ribeye area between the 13th and 14th ribs in cm2. 
i – Fat content between the 13th and 14th ribs in cm. 
j – Percent intramuscular fat. 





Figure 3. Ribeye area between the 17th and 18th ribs (REA17). Changes in REA17 
between treatments over time. The initial difference in REA17 on d 7 was accounted for 
by re-analyzing d 42 and 84 with d 0 as a covariate, as signified by †. Within day, a 
double asterisk (**) signifies that treatments differ at P ≤ 0.05 while a single asterisk (*) 
signifies a tendency for treatments to differ at P < 0.07. Pooled Standard error of the 




























 Fat supplementation has long been utilized to improve the health and performance 
of animals, including horses. Dietary omega-3 fatty acids have been shown to elicit 
several health benefits, including improved immune function and overall health (King et 
al., 2008). One potential downfall of supplementing n-3 fatty acids like EPA and DHA is 
that they are frequently marine-derived, which can create palatability issues. CLA is a 
potentially more palatable alternative to dietary n-3 fatty acids that may offer benefits 
like that of n-3 fatty acids, such as reduction of body fat content and increase of lean 
muscle mass (O’Quinn et al., 2000; Ostrowska et al., 1999). The purpose of this study 
was to investigate if elevated dietary CLA would alter lean muscle mass and fat 
deposition in young, developing horses. Data from previous equine studies have shown 
that CLA can affect plasma fatty acid levels when compared to a control oil. Headley et 
al. (2012) utilized corn oil as a control, but soybean oil was utilized in this study as it is 
the most readily available and is a fat supplement widely used in the equine industry to 
finish out performance horses.  
Palatability 
 To our knowledge, the supplementation rate of CLA in previous equine studies 
has not exceeded 1.0% of total diet. Supplementing CLA at 1.0% of total diet increased 
ADG and decreased fat content in hogs (Thiel-Cooper et al., 2001), but did not exhibit 
the same change in body composition in horses at a lower inclusion rate (Headley et al., 
2012), which suggests a higher level of supplementation may be required to achieve 
results similar to that of other species. Results from the initial phase of this study 
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indicated that refusals increased significantly when CLA was supplemented above 5.0% 
of the total daily concentrate diet, which suggests that supplementing at or below that 
level would prevent a reduction in feed intake levels. However, during phase II CLA 
could not be supplemented above 1.5% of total diet without significant refusals. This 
could possibly be the result of individual horse preference, some horses during either 
phase of this study would consume their concentrate without any added oil but would 
stop eating completely when supplemented with CLA, while others never had any 
refusals no matter how much CLA was supplemented. Horses that stopped eating 
completely upon beginning CLA supplementation were removed from the study before d 
0. Further study with greater numbers is needed to clarify the reason for the conflicting 
results and to clarify the maximum possible inclusion rate of CLA supplementation in 
horses. 
Body Composition 
 Results of this study indicate that CLA supplementation does not influence BW, 
BCS, or other growth performance measurements like heart girth and crest 
circumference. This coincides with results of Headley et al. (2012), who did not find an 
effect of CLA on body composition. While previous literature has shown that CLA 
exhibits an anti-adipogenic effect on body composition in numerous species including 
swine, rats, and humans (Ostrowska et al., 1999; O’Quinn et al., 2000; Thiel-Cooper et 
al., 2001), the same effect has not been successfully seen in the horse. The effect of CLA 
on body composition has been shown to be quite variable across species, so it is possible 
that CLA does not exert the same anti-adipogenic effect in equines as seen in other 
species. In contrast to data seen in hogs, CLA supplementation in mature women did not 
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alter BW or BMI but did decrease hip circumference (Madry et al., 2016). Alternatively, 
it is possible that the effect of CLA on body composition is dependent on pre-existing 
adiposity, and as such may be more evident in obese or insulin-resistant horses than in 
young, developing horses. For instance, both Chin et al. (1994) and Noto et al. (2006) 
reported a significant improvement in lipid metabolism in insulin-resistant rats 
supplemented with CLA. In this study, there was a tendency for heart girth to be higher in 
CLA supplemented horses over time, so there is still potential for CLA to affect body 
composition. Future studies with prolonged CLA supplementation periods are needed to 
help clarify the effect of CLA on equine body composition.  
Ultrasound 
 Data from the current study indicates that CLA does not affect body fat content, 
including RFT, IMF, BF13, and BF17. These results are in contrast with previous 
literature that demonstrated t10, c12-CLA supplementation alters body composition by 
decreasing body fat content in finishing swine (Ostrowska et al., 1999; O’Quinn et al., 
2000; Thiel-Cooper et al., 2001). This difference may be the result of a species-dependent 
effect of CLA supplementation, but results from the current study also contradict data 
from Headley et al. (2012) that indicated a tendency for CLA to increase RFT in horses. 
Alternatively, if the effect of CLA is dependent upon pre-existing adiposity, then this 
difference may be the result of supplementing CLA to young, developing horses as 
opposed to mature horses with higher fat content. Further study is needed to clarity the 
reason for the conflicting results. 
 While data from this study do not indicate a difference in REA13 between 
treatment groups, there was a tendency for REA17 to be higher in CLA supplemented 
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horses. These data coincide with results of previous literature demonstrating an increase 
in lean muscle mass because of CLA supplementation (O’Quinn et al., 2000; Ostrowska 
et al., 1999; Thiel-Cooper et al., 2001). However, the mechanism of action controlling 
this increase remains unclear. An increase in lean muscle mass due to CLA 
supplementation contradicts previous study demonstrating a shift in muscle fiber type 
from type IIB to type I as a result of CLA supplementation, which would cause the 
muscle fiber to shrink in size (Kim et al., 2016). It would be useful to take muscle 
biopsies in addition to ultrasound measurements to track any changes in muscle fiber type 
over the supplementation period to clarify the effect of CLA on lean muscle mass. 
Additionally, while several studies have shown that dietary CLA is absorbed and 
incorporated into circulation as early as 2 to 6-wk of supplementation (Headley et al., 
2012; King et al., 2008), the incorporation into tissues inevitably takes longer and 
changes to the tissue longer still. Plasma fatty acid levels were not able to be analyzed for 
this study, but would be a beneficial addition to track changes over the supplementation 
period and to help determine how long it will take CLA to incorporate into tissues. As 
such, it is possible that a longer supplementation period will be necessary to demonstrate 





 While the inclusion rate of this study was higher than previous studies, the 
maximum inclusion rate of CLA in the equine diet remains unclear in an equine model 
after the two phases of this study. Dietary supplementation of CLA at 0.015% BW over a 
12-wk feeding period tended to increase lean muscle mass but did not affect overall 
growth performance or body fat content. Results of this current study indicate that CLA 
may be a beneficial supplement for performance horses that require more muscle mass. It 
would be beneficial to include muscle biopsies and plasma fatty acid analysis in future 
studies to further clarify the necessary length of supplementation and in order to see any 
potential effect of CLA on changes in muscle fiber type and lean muscle mass. Further 
study to determine the most appropriate inclusion rate in the equine diet may also help 
clarify the effect of CLA on body composition, including fat content, which may have 
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$1,000 awarded by the Department of Agricultural Sciences and Engineering Technology 
at SHSU. 
SHSU College of Sciences Special Graduate Scholarship Award 2016-2017 
$1,500 per semester for 2016 and Spring 2017 
USHJA/IHSA Sportsmanship Award Winner, Zone 7, Region 5 2015 
Teresa L. McDonald Horsemanship Challenge National Competitor 2015 
TruScholar Recipient 2014 
$3000 to conduct original research resulting in “Evaluation of inter-day variation of 
horses on total fecal collection” 
Missouri Bright Flight Scholarship 2011-2015 
Up to $3,000 annually based on GPA and ACT scores 
AT&T Foundation Scholarship 2011-2013 
$1,500 annually 






Animal Physiology Statistics 
Reproductive Physiology Genetics 
Organic Chemistry Animal Health 
Biochemistry: Metabolism Animal Nutrition 
Equine Reproductive Practicum Microbiology 
 
SKILLS & TECHNIQUES 
 
Equine Ultrasounding   Total Fecal Collection               Artificial Insemination 
IV/IM Injections                    Equine/Bovine Blood Collection          Western Blot Testing 
Statistical Analysis System      YSI Glucose/Lactate Analysis                Semen Evaluation 
  
GRADUATE RECORD EXAMINATION 
 
Verbal 160 (85%)                   Quantitative 158 (70%) Analytical Writing 5.0 (93%) 
 
